Document Detail


Dual antiplatelet therapy is not optimal for stroke prevention in patients with atrial fibrillation.
MedLine Citation:
PMID:  20088990     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The superior efficacy of oral anticoagulation over aspirin for prevention of recurrent stroke in patients with atrial fibrillation is widely acknowledged. However, oral anticoagulation therapy is notorious for having a narrow therapeutic index, numerous drug and dietary interactions, and a significant risk of serious bleeding. The value of dual antiplatelet therapy for stroke prevention in patients with atrial fibrillation has been assessed in the ACTIVE A trial. In this study, the relative risk of primary events was significantly decreased in patients allocated clopidogrel and aspirin compared with patients receiving aspirin alone. However, the relative risk of major bleeding was also significantly increased. This article analyses critically the role of dual antiplatelet therapy for stroke prevention in patients with atrial fibrillation.
Authors:
A Chamorro
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of stroke : official journal of the International Stroke Society     Volume:  5     ISSN:  1747-4949     ISO Abbreviation:  Int J Stroke     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-01-21     Completed Date:  2010-03-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101274068     Medline TA:  Int J Stroke     Country:  England    
Other Details:
Languages:  eng     Pagination:  28-9     Citation Subset:  IM    
Affiliation:
Comprehensive Stroke Center, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biom?diques August Pi i Sunyer, Barcelona, Spain. achamorro@ub.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Atrial Fibrillation / complications*
Drug Therapy, Combination
Humans
Platelet Aggregation Inhibitors / adverse effects*,  therapeutic use*
Risk Factors
Stroke / complications*,  prevention & control*
Vitamin K / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 12001-79-5/Vitamin K

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hand up! Yawn and raise your arm.
Next Document:  Microalbuminuria in cerebrovascular disease: a modifiable risk factor?